loader
Please Wait
Applying Filters...

Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Vatiquinone, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Vatiquinone

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    2D Structure
    1. Also known as: 1213269-98-7, Epi-743, Alpha-tocotrienol quinone, Epi 743, Alpha tocotrienol quinone, .alpha.-tocotrienol quinone
    Molecular Formula
    C29H44O3
    Molecular Weight
    440.7  g/mol
    InChI Key
    LNOVHERIIMJMDG-XZXLULOTSA-N
    FDA UNII
    6O85FK9I0X
    Vatiquinone has been investigated for the treatment and prevention of Retinopathy, Rett Syndrome, Genetic Disease, Noise-induced Hearing Loss, and Methylmalonic Aciduria and Homocystinuria,Cblc Type.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-[(3R,6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione
    2.1.2 InChI
    InChI=1S/C29H44O3/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8,32)19-17-26-25(7)27(30)23(5)24(6)28(26)31/h12,14,16,32H,9-11,13,15,17-19H2,1-8H3/b21-14+,22-16+/t29-/m1/s1
    2.1.3 InChI Key
    LNOVHERIIMJMDG-XZXLULOTSA-N
    2.1.4 Canonical SMILES
    CC1=C(C(=O)C(=C(C1=O)C)CCC(C)(CCC=C(C)CCC=C(C)CCC=C(C)C)O)C
    2.1.5 Isomeric SMILES
    CC1=C(C(=O)C(=C(C1=O)C)CC[C@@](C)(CC/C=C(\C)/CC/C=C(\C)/CCC=C(C)C)O)C
    2.2 Other Identifiers
    2.2.1 UNII
    6O85FK9I0X
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Alpha-tocotrienol Quinone

    2. Epi-743

    2.3.2 Depositor-Supplied Synonyms

    1. 1213269-98-7

    2. Epi-743

    3. Alpha-tocotrienol Quinone

    4. Epi 743

    5. Alpha Tocotrienol Quinone

    6. .alpha.-tocotrienol Quinone

    7. 6o85fk9i0x

    8. 2,5-cyclohexadiene-1,4-dione, 2-((3r,6e,10e)-3-hydroxy-3,7,11,15-tetramethyl-6,10,14-hexadecatrien-1-yl)-3,5,6-trimethyl-

    9. 2-((r,6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trien-1-yl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione

    10. Vatiquinone [usan]

    11. Vatiquinone [usan:inn]

    12. Unii-6o85fk9i0x

    13. Vatiquinone [inn]

    14. Vatiquinone [jan]

    15. Vatiquinone (jan/usan)

    16. Schembl503125

    17. (r)-alpha-tocotrienol Quinone

    18. Chembl1812161

    19. Schembl14639355

    20. Dtxsid90153231

    21. Bcp21072

    22. Ex-a5566

    23. Db11917

    24. 2-[(3r,6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione

    25. Hy-16772

    26. Cs-0012384

    27. D10407

    28. A937320

    29. Q27265220

    30. Epi 743;epi743; Vatiquinone; Alpha-tocotrienol Quinone

    31. 2-((3r,6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trien-1-yl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione

    32. 2-[(3r,6e,10e)-3-hydroxy-3,7,11,15-tetramethyl-6,10,14-hexadecatrien-1-yl]-3,5,6-trimethyl-2,5-cyclohexadiene-1,4-dion

    2.4 Create Date
    2010-07-06
    3 Chemical and Physical Properties
    Molecular Weight 440.7 g/mol
    Molecular Formula C29H44O3
    XLogP37.4
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count3
    Rotatable Bond Count12
    Exact Mass440.32904526 g/mol
    Monoisotopic Mass440.32904526 g/mol
    Topological Polar Surface Area54.4 Ų
    Heavy Atom Count32
    Formal Charge0
    Complexity857
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count2
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of Leigh syndrome

    Treatment of mitochondrial disease

    Post Enquiry
    POST ENQUIRY